Skip to main content

Table 2 Intention to treat analysis: Clinical and biological responses to IV glucose or sublingual sugar administration among children with hypoglycaemia (BGC < 60 mg/dl) in Mali

From: Sublingual sugar for hypoglycaemia in children with severe malaria: A pilot clinical study

  Sublingual Sugar (SLS) Intravenous Glucose (IVG) p
  n = 14
(95%CI)
n = 9
(95%CI)
 
Primary Outcome measure    
- Treatment Response (reaching 60 mg within 40 minutes) 10/14 (71%) 6/9 (67%) 0.81
Secondary outcome measures    
- Early treatment responsea 9/14 (64.3%) 6/9 (67%) 0.91
- Relapseb (as % of treatment responders) 3/10 (30%) 1/6 (17%) 0.55
-CGmaxd(mg/dl) 43.4 (25.8–62.5) 46.2 (19.1–73.2) 0.60
-Treatment delay (mins)e < 5 18.9 (6.4–31.6) -
Case Fatality 1 (7%) 1 (11%) NS
  1. a defined as a significant blood glucose gain (> 10 mg/dl) at or before 20 minutes
  2. b defined as children who reached a normal glycaemia 3.3 mmol/L (60 mg/dl), but failed to maintain it
  3. c defined as the difference between baseline BGC and the peak glucose concentration (on the first-line treatment) within the first 40 minutes
  4. d the time from confirmation of hypoglycaemia to the beginning of treatment. Treatment delay for SLS was always less than 5 minutes and was not recorded precisely so 5 minutes was taken as a conservative estimate; for IVG, treatment delay was the observed value.